Dr. Robert A. Kaiser is a board-certified toxicologist who serves as a consultant in experimental design, interpretation, and reporting for XenoTherapeutics’ pre-IND and IND-enabling studies and submissions.  He served as a Toxicology Study Director for a major CRO for 11 years, designing and reporting countless IND-enabling studies for test articles ranging from classic small molecule pharmacologic agents through advanced biological therapeutics, compliant with US FDA Good Laboratory Practice (GLP) requirements.  


Dr. Kaiser currently supports the development and reporting of therapeutic candidates at XenoTherapeutics, blending scientific and regulatory experiences into an invaluable academic approach that assists the company during its transition from academic discoveries to clinical realities.


Dr. Kaiser earned his Ph.D. in Biochemistry at the University of Nevada, Reno, where he studied vascular smooth muscle pharmacology and endothelial cell signaling, and later completed his post-doctoral training in Molecular Cardiovascular Biology under Jeffery Molkentin at the Cincinnati Children’s Hospital Medical Center, with a concentration on large and small animal surgical models of disease.  Dr. Kaiser began his career as a toxicologist and safety pharmacologist in the CRO industry, where he led an international team of scientists to standardize study design, execution and reporting for Biotech and Pharma Sponsors, particularly for cardiovascular safety studies in multiple animal models. During his time there, Dr. Kaiser completed the requirements for certification by the American Board of Toxicology and contributed to defining industry best practices for integrated pharm/tox study design and social housing considerations for large animals in regulatory studies.